Occurred in 8.8% of participants on 9 mg and 20.9% on 12 mg, compared to 0.7% on placebo Dose-dependent (higher dose, higher risk) Generally described as mild Rarely led to discontinuation Why this matters: Dysesthesia was not reported in the Phase 2 trial
After all, that's what finally led me to make this choice.
Supplementary Data 2) 16
It's like they have helped accentuate the effect of topical skincare products I
GLP1s have also been shown to benefit blood sugar balance by protecting the pancreatic cells that produce insulin. Stomach: Slows digestion, especially emptying of food from the stomach, thereby enhancing feelings of fullness and reducing the rate of absorption of sugar and carbohydrates from foods. Brain: Reduce perceived appetite, often leading to less intense sense of hunger and fewer cravings, thus easing efforts to moderate food intake. Muscle: Improves the sensitivity of muscle cells to insulin signaling leading to increased glucose utilization for energy. Adipose (fat) tissue: Encourages greater fat tissue breakdown and fat cell insulin sensitivity, which has a multitude of anti-inflammatory and generally metabolically supportive impacts. What you need to know before starting While GLP-1s are generally considered low risk medications, there are several important factors to consider before beginning treatment and again, as always consult with at least one medical professional before beginning therapy to ensure appropriate use and treatment monitoring
First, GLP-1 receptor agonists stimulate glucose-dependent insulin secretion from pancreatic -cells
